Ocrelizumab: long-term data
Biotin in progressive MS
Increased myocardial infarction risk in MS
No adverse impact with frequent gadolinium exposure
Emerging treatment approaches: targeting Bruton’s tyrosine kinase Read More
Latest News
ECTRIMS Poster Picks – Wednesday, October 10
October 10, 2018Wednesday, October 10, 2018 – Poster Session 1 – 5:00 – 7:00 PM
Here are Steven’s Top 10 poster topics at ECTRIMS for Wednesday, October 10, 2018. Read More
Laquinimod program cancelled in MS
September 6, 2018Teva Pharmaceuticals has announced that it will no longer pursue the commercial development of laquinimod, a small-molecule aryl hydrocarbon receptor activator, in neurodegenerative diseases. The development and commercialization rights will revert back to Active Biotech, the company that originated the molecule. Read More
Canadian real-world study of aripiprazole LAI in schizophrenia
August 23, 2018POSTER DISCUSSION
Presented at the American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, Florida, May 29 – June 1, 2018
The first Canadian naturalistic study in patients with schizophrenia has reported high rates of remission rates and low rates of relapse with long-acting aripiprazole over a one-year period (Oluboka et al. ASCP 2018; abstract). Read More